|
|
 |
HYDROXYPROPYL CELLULOSE, LOW SUBSTITUTED Drug Excipient Business Development Opportunity Report, 2024 |
$399.00 |
|
$399.00 |
|
|
 |
HALAVEN Drug Profile, 2024 |
$399.00 |
|
$399.00 |
|
|
 |
HYDROGENATED CASTOR OIL Drug Excipient Business Development Opportunity Report, 2024 |
$399.00 |
|
$399.00 |
|
|
 |
HARVONI Drug Profile, 2024 |
$399.00 |
|
$399.00 |
|
|
 |
GILOTRIF Drug Profile, 2024 |
$399.00 |
|
$399.00 |
|
|
 |
HORIZANT Drug Profile, 2024 |
$399.00 |
|
$399.00 |
|
|